Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia

Recruiting now · Phase 3

Conditions studied: Paronychia, EGFR-TKI, ALK-TKI

In brief

To assess the clinical efficacy of add-on topical timolol 0.5% eye drops to betamethasone valerate 0.1% for the treatment of EGFR-TKI and ALK-TKI induced paronychia.

Key facts

Study ID

NCT06643416

Run by

Queen Mary Hospital, Hong Kong

People needed

40

Starts

2024-10-09

Expected to finish

2025-12-31

Last updated by the study team

2024-10-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 18 years or above, either males or females.
• Received EGFR-TKI and ALK-TKI, namely gefitinib, erlotinib, afatinib, osimertinib, amivantamab, dacomitinib, mobocertinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib for the treatment of non-small cell lung cancer.
• Paronychia (fingernails, toenails, or both) as an adverse event from EGFR-TKI use
• Written informed consent obtained from patient
• Subjects are diagnosed with advanced non-small cell lung cancer

You may not qualify if…

• 1. Age below18
• 2. Patients who are allergic to, or contraindicated to topical timolol use
• 3. Pregnant women or nursing mother
• 4. Non-consenting patients
• 5. Subjects are not diagnosed with advanced non-small cell lung cancer

Where it is running

• Queen Mary Hospital — Hong Kong, Hong Kong (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.